CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,795 Patients From 22 Studies Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort Rotational Atherectomy Followed by Drug-Coated Balloon Dilation for Left Main In-Stent Restenosis in the Setting of Acute Coronary Syndrome Complicated with Right Coronary Chronic Total Occlusion SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? Can the Vanishing Stent Reappear? Fix the Technique, or Fix the Device? AIM2-driven inflammasome activation in heart failure Coronary Artery Calcium Is Associated with Left Ventricular Diastolic Function Independent of Myocardial Ischemia Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement

Original ResearchSeptember 2019

JOURNAL:JACC Cardiovasc Interv. Article Link

Physiologic Characteristics and Clinical Outcomes of Patients With Discordance Between FFR and iFR

SH Lee, KH Choi, JM Lee et al. Keywords: coronary artery disease; coronary flow reserve; fractional flow reserve; instantaneous wave-free ratio; prognosis

ABSTRACT


OBJECTIVES - The study evaluated the physiologic characteristics of discordant lesions between instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) and the prognosis at 5 years.

 

BACKGROUND - FFR or iFR have been standard methods for assessing the functional significance of coronary artery stenosis. However, limited data exist about the physiologic characteristics of discordant lesions and the prognostic implications resulting from these lesions.

 

METHODS - A total of 840 vessels from 596 patients were classified according to iFR and FFR; high iFRhigh FFR (n = 580), low iFRhigh FFR (n = 40), high iFRlow FFR (n = 69), and low iFRlow FFR (n = 128) groups, which were compared with a control group (n = 23). The differences in coronary circulatory indices including the coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and resistance reserve ratio (RRR) (resting distal arterial pressure × mean transit time / hyperemic distal arterial pressure × hyperemic mean transit time), which reflect the vasodilatory capacity of coronary microcirculation, were compared. Patient-oriented composite outcomes (POCO) at 5 years including all-cause death, any myocardial infarction, and any revascularization were compared among patients with deferred lesions.

 

RESULTS- In the low iFRhigh FFR group, CFR, RRR, and IMR measurements were similar to the low iFRlow FFR group: CFR 2.71 versus 2.43 (p = 0.144), RRR 3.36 versus 3.68 (p = 0.241), and IMR 18.51 versus 17.38 (p = 0.476). In the high iFRlow FFR group, the CFR, RRR, and IMR measurements were similar to the control group: CFR 2.95 versus 3.29 (p = 0.160), RRR 4.28 versus 4.00 (p = 0.414), and IMR 17.44 versus 17.06 (p = 0.818). Among the 4 groups, classified by iFR and FFR, CFR and RRR were all significantly different, except for IMR. However, there were no significant differences in the rates of POCO, regardless of discordance between the iFR and FFR. Only the low iFRlow FFR group had a higher POCO rate compared with the high iFRhigh FFR group (adjusted hazard ratio: 2.46; 95% confidence interval: 1.17 to 5.16; p = 0.018).

 

CONCLUSIONS-  Differences in coronary circulatory function were found, especially in the vasodilatory capacity between the low iFRhigh FFR and high iFRlow FFR groups. FFRiFR discordance was not related to an increased risk of POCO among patients with deferred lesions at 5 years. (Clinical, Physiological and Prognostic Implication of Microvascular Status; NCT02186093; Physiologic Assessment of Microvascular Function in Heart Transplant Patients; NCT02798731)